Immunome (NASDAQ:IMNM) Reaches New 1-Year Low – Here’s What Happened

Shares of Immunome, Inc. (NASDAQ:IMNM) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.12 and last traded at $8.15, with a volume of 960264 shares. The stock had previously closed at $8.18.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IMNM. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Finally, Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.50.

Immunome Trading Down 0.4 %

The stock has a 50-day simple moving average of $9.72 and a 200 day simple moving average of $11.49. The company has a market cap of $708.65 million, a price-to-earnings ratio of -1.00 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after buying an additional 1,520 shares during the period. Sequoia Financial Advisors LLC raised its position in Immunome by 11.7% during the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock valued at $202,000 after acquiring an additional 2,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Immunome by 5.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock valued at $441,000 after acquiring an additional 2,005 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock valued at $201,000 after acquiring an additional 3,974 shares during the period. Finally, Wellington Management Group LLP boosted its position in Immunome by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after purchasing an additional 4,874 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.